Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7749573 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8282485 | 0.83 | MEN1 (0.58) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL567578 | 0.83 | MEN1 (0.56) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2187660 | 0.82 | MEN1 (0.55) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12998272 | 0.82 | MEN1 (0.55) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16533483 | 0.82 | MEN1 (0.58) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3560316 | 0.82 | MEN1 (0.55) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL567435 | 0.82 | MEN1 (0.55) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL847723 | 0.82 | KMT2A (0.55) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2187792 | 0.82 | MEN1 (0.55) | SMN1; SMN2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4387980-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2646455-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-1991010679-A2 | RENIN INHIBITING PEPTIDES HAVING AN 'alpha'-HETEROATOM AMINO ACID AT THE P3 POSITION | WARNER LAMBERT CO (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | SMN1; SMN2 2971/4885MEN1 4346/4885KMT2A 4265/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | SMN1; SMN2 4032/4885MEN1 4164/4885KMT2A 3130/4885 |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | SMN1; SMN2 3507/4885MEN1 4235/4885KMT2A 3102/4885 |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | SMN1; SMN2 1750/4885MEN1 3412/4885KMT2A 23/4885 |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | SMN1; SMN2 3994/4885MEN1 4129/4885KMT2A 424/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | SMN1; SMN2 4032/4885MEN1 4164/4885KMT2A 3130/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | SMN1; SMN2 3613/4885MEN1 4306/4885KMT2A 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.